Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.

Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, Bai C, Rui L, Laleau R, Liu F, Ab O, Setiady Y, Yoder NC, Goldmacher VS, Chari RVJ, Pinkas J, Chittenden T.

Blood Adv. 2018 Apr 24;2(8):848-858. doi: 10.1182/bloodadvances.2018017517.

2.

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.

Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, Wilhelm A, Modafferi HA, Singh R, Pinkas J, Goldmacher V, Lambert JM, Chari RV.

Mol Cancer Ther. 2016 Aug;15(8):1870-8. doi: 10.1158/1535-7163.MCT-16-0184. Epub 2016 May 23.

3.

Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing.

Widdison WC, Ponte JF, Coccia JA, Lanieri L, Setiady Y, Dong L, Skaletskaya A, Hong EE, Wu R, Qiu Q, Singh R, Salomon P, Fishkin N, Harris L, Maloney EK, Kovtun Y, Veale K, Wilhelm SD, Audette CA, Costoplus JA, Chari RV.

Bioconjug Chem. 2015 Nov 18;26(11):2261-78. doi: 10.1021/acs.bioconjchem.5b00430. Epub 2015 Sep 30.

PMID:
26355774
4.

High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.

Goldmacher VS, Audette CA, Guan Y, Sidhom EH, Shah JV, Whiteman KR, Kovtun YV.

PLoS One. 2015 Feb 11;10(2):e0117523. doi: 10.1371/journal.pone.0117523. eCollection 2015.

5.

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ.

MAbs. 2014 Mar-Apr;6(2):556-66. doi: 10.4161/mabs.27756. Epub 2014 Jan 8.

6.

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.

Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, Pinkas J, Tibbitts J.

Mol Cancer Ther. 2012 May;11(5):1133-42. doi: 10.1158/1535-7163.MCT-11-0727. Epub 2012 Mar 9.

7.

Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV.

Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2.

8.

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Bl├Ąttler WA, Goldmacher VS.

Cancer Res. 2006 Mar 15;66(6):3214-21.

9.

Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities.

Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R.

J Med Chem. 1992 Aug 21;35(17):3135-41.

PMID:
1507202
10.

G-protein mediation of cannabinoid-induced phospholipase activation.

Audette CA, Burstein SH, Doyle SA, Hunter SA.

Pharmacol Biochem Behav. 1991 Nov;40(3):559-63.

PMID:
1666919
11.

Elevation of brain prostaglandin E2 levels in rodents by delta 1-tetrahydrocannabinol.

Hunter SA, Audette CA, Burstein S.

Prostaglandins Leukot Essent Fatty Acids. 1991 Jul;43(3):185-90.

PMID:
1651514
12.

Detection of cannabinoid receptors by photoaffinity labelling.

Burstein SH, Audette CA, Charalambous A, Doyle SA, Guo Y, Hunter SA, Makriyannis A.

Biochem Biophys Res Commun. 1991 Apr 15;176(1):492-7.

PMID:
1850270
13.
14.

Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid.

Burstein SH, Audette CA, Doyle SA, Hull K, Hunter SA, Latham V.

J Pharmacol Exp Ther. 1989 Nov;251(2):531-5.

PMID:
2553925

Supplemental Content

Loading ...
Support Center